[
    {
        "utterance": "Dr. Anna Moore: Sandin at the College of Human Medicine. Uh prior to joining MSU, which was about three years ago, uh my career all my career pretty much went at Massachusetts General Hospital and Harvard Medical School that I joined as postdoctoral fellow and by the time I left I was a professor at Harvard Medical School, professor in radiology. So, uh my personal interest in science is image guided therapy for metastatic cancers. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to her field, sharing her career history and current position."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um, in the beginning of my career, I used uh iron oxide nanoparticles as contrast agents uh to detect tumors and now we're using them actually as uh carriers as vehicles to deliver therapies and as imaging reporters as well, that's why it's image guided therapy. ",
        "annotations": {
            "signal expertise": "Dr. Anna Moore is explicitly stating her own expertise and qualifications in the field of image-guided therapy, which directly relates to her background and research experience."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So that's it. Um, I mean, I can take tell you more, but I think we should try to keep it short. ",
        "annotations": {
            "process management": "This code applies because Dr. Moore is managing the meeting flow by suggesting a limit to how much information will be shared."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, um, I I'm just going to go the way I see people on the screen, so no or or no, I do have a list here. Okay, let's just go alphabetically. Benjamin. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by deciding the order of participant contributions.",
            "encourage participation": "The speaker is inviting a specific participant, Benjamin, to contribute."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Hi. Uh, I'm Ben Benjamin Bartel. I'm assistant professor just started this year at Arizona State University. I work on uh molecular tools for MRI. My goal is to uh non-invasively resolve and manipulate the neuroimmune system. So I do that with a combination of um uh just direct MRI methods uh through um just image analysis and I also build a host of molecular tools using directed evolution, signaling reporters, direct molecular sensors, etc. all for MRI and all in vivo. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own professional background and research focus, indicating their expertise in the field."
        }
    },
    {
        "utterance": "Dr. Anna Moore: We met yesterday, right? ",
        "annotations": {
            "ask question": "The utterance 'We met yesterday, right?' is a clear example of asking for information or clarification about a past interaction, fitting the definition of 'ask question'."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah, I think we did. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Dr. Anna Moore's statement about meeting previously.",
            "supportive response": "The speaker is expressing agreement with Dr. Anna Moore's inquiry."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, they screwed up a little bit the facilitators and the group, so I was supposed to be in the other group at the beginning. So, but that's fine. So it's all good to see faces that you've seen before. ",
        "annotations": {
            "express humor": "Dr. Anna Moore makes a light comment about a mistake ('they screwed up a little bit'), which can be considered as expressing humor."
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right. Uh Molly. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by transitioning to the next participant's introduction."
        }
    },
    {
        "utterance": "Molly Bright: Hi, I'm Molly Bright. I'm at Northwestern in Chicago. Uh, I also do in vivo work with MRI, but with humans. Um, I mostly look at quantifying aspects of the plumbing. So blood flow supplied to the tissue, how that blood flow is regulated or misregulated, um, aspects of oxygen delivery and metabolism. Uh, but I also like to think about how all of that vascular infrastructure supports or doesn't support healthy neural function. So, um, I do a lot of work now in in patients thinking about rehabilitation. So what can we do after something's happened to try to recover and repair both the neural and vascular systems. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to her work with MRI in humans.",
            "develop idea": "The speaker is expanding on her research focus, providing details about her work."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Wonderful. Dylan. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by moving through a list of participants to introduce or acknowledge them."
        }
    },
    {
        "utterance": "Dylan Burnette: Hi, I'm Dylan Burnette. Um, I am an associate professor at Vanderbilt University. I just am just barely on the other side of tenure now. Uh although I still feel like I have like new people problems. Um, but I am a cell biologist by training and so I've been using light microscopes for about 20 years or so, a little bit more unfortunately. Um as I'm getting older. Uh to to study uh the cell skeleton. And so my my lab we kind of took that interest in in the cell skeleton to ask a very simple question. How does a heart grow on a single cell level? Meaning how does a single heart muscle cell physically get bigger? And that is one of the main drivers of our lab. Uh and we do attack that in multiple ways and it occurred to us a few years ago, actually about a year ago now that we could use the same technologies we're using to start mimicking what's happening inside of patients in in a in a uh basically a dish. And so we are now developing uh systems to mimic ischemia and reperfusion injury in our cardiac myos and that's allowed us to start doing screening and I have no idea what I'm doing and it's phenomenal. I have we're having a very good time. Uh and so we are kind of all over the place. We're we're looking at individual sarcomeres and we're looking to find some drugs. ",
        "annotations": {
            "signal expertise": "Dylan explicitly states his position as an associate professor and his background in cell biology.",
            "express humor": "Dylan makes a humorous comment about his 'new people problems' and finding his current situation 'phenomenal' and 'having a very good time'."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. All right, sounds good. Morteza. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by introducing the next speaker.",
            "encourage participation": "Dr. Anna Moore is inviting Morteza to contribute by saying his name, indicating it's his turn to speak."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Hi, my name is Morteza Mahmoudi and uh I'm an assistant professor at Michigan State University. My work is uh focused on nanomedicine and regenerative medicine and basically we use imaging technique to basically probe nanoparticles. if we use them for like therapeutic approaches like MRI approaches, if we use like magnetic based nanoparticles. Uh, but uh most importantly we try to understand what happens at the surface of nanoparticles. So for that purpose we combine cryo transmission electron microscopy and uh 3D constructed imaging model to basically see the 3D structure of the nanoparticles and how they interact with proteins and at the larger scale how they interact with different cell types and what are their uh trafficking inside the cells. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his qualifications and area of expertise.",
            "develop idea": "The speaker elaborates on his work, providing details about his research focus and methods."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Paris. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Paris Perdikaris: Hello everyone. So my name is Paris Perdicarris and I'm assistant professor at the Department of Mechanical Engineering at the University of Pennsylvania. Um, my background actually is in applied mathematics and my work is focused on developing machine learning methods and computational tools for modeling and simulation of physical and biological systems. I think most relevant to this meeting in some is some work I'm pursuing on physics based filtering of um uh in vivo MRI uh with a focus on 4D flow MRI and reconstructing blood flow and measurements in a way that the underlying physics is satisfied, so principles like mass and momentum conservation and then using those principles to infer auxiliary measurements that um cannot be measured by imaging such as blood pressure, uh shear stresses, um uh and so forth. So the idea there is really to understand the role of hemodynamics in determining organ function and uh you know, predicting biomarkers that are relevant to cardiovascular disease. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own expertise and qualifications related to the task.",
            "clarify goal": "The speaker mentions his research goals and focus areas."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Wonderful, Lisa. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive sentiment towards Lisa.",
            "acknowledge contribution": "The speaker is also acknowledging Lisa, though briefly."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Hi everyone, I'm Lisa Poulikakos. I'm an assistant professor at UC San Diego. My research works on nanophotonics, so the study and manipulation of light at the nanoscale. Um, and some questions I'm really interested in is how can we scale down the complex manipulation of light. So a lot of these really sophisticated imaging techniques using state of the art nano optics can actually be realized on a single optical surface, which is then uh nano patterned in intricate ways and then can really be easily deployed in a variety of in vivo and ex vivo applications. Um and some questions that I find interesting um recently are how can we uh enhance polarized light matter interactions to learn more about the structural properties of molecules or tissues, for example. ",
        "annotations": {
            "signal expertise": "Lisa Poulikakos explicitly states her own expertise in nanophotonics and her research interests."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, thank you. Crystal. ",
        "annotations": {
            "process management": "This code applies because the utterance is about moving the meeting forward by calling on the next person to speak, thus managing the meeting flow."
        }
    },
    {
        "utterance": "Crystal Rogers: Hi everyone. Uh my name is Crystal Rogers and I am an assistant professor at UC Davis. I am a developmental uh molecular and cell biologist and my research focuses on on understanding um the roles of transcription factors and cell cell adhesion molecules in regulating the process of the epithelial to transition. So I study neural crest cells um and those cells are really dynamic and they make a lot of different um adult tissues, but probably more relevant to this group, uh all of the molecular mechanisms that allow those cells to undergo EMT are then re uh reused by cancer cells to metastasize. And so what we are doing in my lab is really trying to get at the basal function of the proteins that allow these cells to undergo EMT and to migrate and differentiate and then um at least my postdoc is really interested in trying to define whether those functions um are conserved in disease states. And so we do a lot of fixed and live imaging of these cells to get at um how the collective migration works um and and the paths that these cells take and then um hopefully how that's affected by perturbations of these different proteins. ",
        "annotations": {
            "signal expertise": "The speaker is explicitly stating their own expertise and qualifications related to their research area."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Very, very interesting. ",
        "annotations": {
            "supportive response": "The utterance expresses a positive evaluation of what has been shared by the other participants, indicating engagement and validation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Right in line with what we're doing too, so okay. Uh Mark. ",
        "annotations": {
            "supportive response": "Dr. Anna Moore expresses agreement and alignment with Crystal Rogers' research area.",
            "process management": "Dr. Anna Moore transitions to the next person, Mark, to speak."
        }
    },
    {
        "utterance": "mark sellmyer: that we can't do at this point. And another the other component is really around imaging gene and cell therapies and if we can image it and control it then perhaps we can get into that, you know, positive feedback loop of modulating something in the therapy and then seeing how that changes. So, um, thanks. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of using imaging for gene and cell therapies to create a positive feedback loop.",
            "identify gap": "The speaker mentions something that 'we can't do at this point', indicating a current limitation.",
            "develop idea": "The speaker elaborates on the concept of imaging and controlling gene and cell therapies."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh I just don't want to mispronounce your name. Sixian, Sixian, is that the right way to say it? ",
        "annotations": {
            "ask question": "Dr. Anna Moore is requesting information or clarification on the pronunciation of Sixian's name."
        }
    },
    {
        "utterance": "Sixian You: Uh, yeah, close enough. So my name is uh Sixian You. Yes. Uh, so I'm assistant professor in electrical engineering at MIT. I just started uh this March. Uh, I did my PhD in UIUC uh in label free microscopy. And then I did my uh postdoc in Berkeley in computational imaging. So my new lab uh the goal is to see how to use optics and algorithms to enable breakthroughs in biomedicine, especially the clinical adoption of microscopy in different uh biomedical situations like early cancer diagnosis, image guided therapies and neuroimaging. So I'm very interesting this session uh the reason I've never done anything like image guided therapies before, but uh I'm very curious how can I contribute? How can I use label free imaging, how can I use optics and algorithms to enable point of procedure diagnosis uh or point of procedure real time monitoring of the therapeutic process. Uh, what role would a resolution of cellular dynamics mean in the in the process of imaging guided therapies. ",
        "annotations": {
            "ask question": "He asks questions about how he can contribute, how label-free imaging can be used, and about the role of resolving cellular dynamics in image-guided therapies.",
            "signal expertise": "He mentions his background in electrical engineering at MIT, his work on label-free microscopy, and computational imaging.",
            "encourage participation": "He invites discussion by asking how he can contribute to the session."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Thank you so much. And then there's other people who are not on my list. I don't know if you guys want to introduce yourself. Um. ",
        "annotations": {
            "encourage participation": "Dr. Anna Moore invites others to introduce themselves, encouraging participation.",
            "process management": "Dr. Anna Moore is managing the meeting process by ensuring all participants introduce themselves."
        }
    },
    {
        "utterance": "Arne Bakker (he/him) | CZI: So I'll just briefly say hi if that's okay just to you know who I am. I'm Arne Bakker, I'm at CZI, I'm the director of meetings and community um and so me and my team we host meetings like this about 15 to 20 times a year for the the the the scientists that CZI funds to really uh hope to encourage collaboration and sharing of knowledge. Um and I have a PhD in immunology and did my postdoc at Berkeley and my PhD at the Netherlands Cancer Institute in Amsterdam uh hence my interest in this topic. Uh but I'm mostly here to observe so I'm going to probably throw my camera off and and listen in but uh looking forward to hearing the conversation. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his academic background and experience in immunology, indicating his expertise.",
            "process management": "The speaker clarifies his role in the meeting as primarily observational and mentions adjusting his participation by turning off his camera."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh Sandra, do you want to say a couple of words? ",
        "annotations": {
            "ask question": "Dr. Anna Moore is asking Sandra a question about whether she wants to say a couple of words.",
            "encourage participation": "Dr. Anna Moore is inviting Sandra to contribute to the conversation."
        }
    },
    {
        "utterance": "Sandra Laney - Walder Foundation: Yeah, just really quickly. I'm I'm a guest. I'm from the Walder Foundation based in the Chicago region um and I'm the senior program uh director for science innovation. So really just here as an observer looking forward to hearing the conversation. I also will probably shut my camera off and just participate as a butterfly on the wall. ",
        "annotations": {
            "express humor": "The speaker makes a joke about participating 'as a butterfly on the wall'.",
            "None": "No other relevant code applies to this utterance as the primary function is self-introduction with a humorous remark."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Um so um I guess the first thing we need to do is to select a person uh who's going to be recording uh all the great thoughts that hopefully come come out of this meeting. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by discussing the procedural aspect of selecting a recorder.",
            "assign task": "The speaker is assigning the task of recording the meeting's proceedings to one of the attendees."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I did it last time, so I'm not going to do it this time, but it was actually very fun. So somebody else should have that opportunity. You're just writing down sketches and then everybody likes you because you did the work. So. ",
        "annotations": {
            "process management": "The speaker is discussing the task of recording the meeting and suggesting someone else should do it this time.",
            "encourage participation": "The speaker is inviting others to take on the role of recording, encouraging participation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: That is very true Ben. So Ben did it the last time yesterday and he did an an amazing job. ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore verbally recognizes Ben's input and effort in documenting their previous meeting.",
            "supportive response": "Dr. Anna Moore expresses agreement and a positive evaluation of Ben's contribution."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a brief acknowledgment without additional substance."
        }
    },
    {
        "utterance": "Dr. Anna Moore: And uh as uh Andrew pointed out, you don't need to fill up that slide uh right away because I guess I guess there's some I don't know, interference or something. My internet is not working very great either. So uh you can just write it down somewhere and then transfer it on the slide. So Ben, do you do you want to just basically give people like a couple of ideas how to do that? So they because they they will look a little bit scared. ",
        "annotations": {
            "process management": "Dr. Anna Moore is managing the meeting flow by addressing a practical issue and suggesting an alternative approach.",
            "encourage participation": "Dr. Anna Moore asks Ben to provide ideas, inviting him to contribute his thoughts."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Sure. We're um so you know, we all had a conversation yesterday that when people would make a point, they come in and say like, I don't know, we could one thing was we collect more data than we use these days. And so I just wrote that down. Somebody else said, you know, I'm involved in really these large scale projects and we try to collect data for other people. Like, okay, well, put those things together and I just started cluster together the the main points people were making. And they ended up being in about three general categories. And so at the end, I was like, hey everybody, things kind of went into these three categories. That's great. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing a previous conversation and explaining how he organized the points made during that conversation.",
            "develop idea": "The speaker is explaining and elaborating on his approach to organizing the points from the previous conversation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh we we we sure did. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or confirmation with a previous statement or action, showing support without adding new content.",
            "None": "No additional code seems necessary as the utterance primarily serves to acknowledge or confirm."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It's great to be appreciated. I'm just trying to sell it. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive sentiment towards the appreciation received.",
            "express humor": "The speaker humorously downplays his role, saying 'I'm just trying to sell it.'"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Thank you, appreciate that too. All right, so any volunteers? ",
        "annotations": {
            "acknowledge contribution": "Dr. Anna Moore is thanking and appreciating Benjamin's offer.",
            "ask question": "Dr. Anna Moore is asking for volunteers, which is a request for information or action from the group.",
            "encourage participation": "Dr. Anna Moore is encouraging others to participate by asking for volunteers."
        }
    },
    {
        "utterance": "Sixian You: That is what. I can do it. I'm a newbie in image guided therapies anyway, so I I'm here to absorb and learn. ",
        "annotations": {
            "process management": "The speaker volunteers for the task of recording notes, which is a part of process management."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Sixian, thank you so much. That's uh great. So it's actually up to you. You can write, you know, write in the slide if you want. It's up to you or on the, you know, piece of paper on or on the computer screen and then. ",
        "annotations": {
            "process management": "Dr. Anna Moore is guiding the process of how the discussion should be recorded."
        }
    },
    {
        "utterance": "Sixian You: Uh, yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: No, no, no, it's slide 42. ",
        "annotations": {
            "process management": "This code applies because Dr. Anna Moore is managing the meeting flow by specifying the current slide number."
        }
    },
    {
        "utterance": "Sixian You: 42. Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, it's the recovery slide or is the original slide? ",
        "annotations": {
            "ask question": "The speaker is requesting clarification on which slide is being referred to, either the recovery slide or the original slide."
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Whichever one is for our room. It doesn't matter what number slide it is. If it's the one for 2.3. ",
        "annotations": {
            "supportive response": "The speaker is being supportive and accommodating regarding the task of note-taking.",
            "process management": "The speaker is making a comment that helps manage the meeting process, specifically regarding how to handle note-taking."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So we're saying there's versions of the document and we should use the one that doesn't say recovery somehow just so if I understood correctly. ",
        "annotations": {
            "ask question": "The speaker is requesting clarification on which document version to use.",
            "acknowledge contribution": "The speaker is referencing and building upon a previous discussion about document versions."
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Got it. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: That makes sense. Okay. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement or validation for a previous statement, indicating understanding and support without adding new content."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I have a slide that doesn't say recovery. Well, okay. ",
        "annotations": {
            "process management": "Dr. Anna Moore is guiding the process by referring to specific slides and their content, helping to manage the meeting flow."
        }
    },
    {
        "utterance": "Sixian You: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: already entered her name. ",
        "annotations": {
            "process management": "The speaker acknowledges the assignment of a task (note-taking) to someone else (Sixian You).",
            "acknowledge contribution": "The speaker acknowledges Dr. Anna Moore's action of selecting Sixian You for the task."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, you can just do that. Okay, great, excellent. ",
        "annotations": {
            "supportive response": "Dr. Moore is expressing agreement and approval with a positive evaluative tone.",
            "acknowledge contribution": "Dr. Moore acknowledges and agrees with the previous suggestion."
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right, so here we go. Um from models to humans. Um so basically the question is we have uh a lot of uh drugs in the pipeline in in uh petri dishes in the labs uh that were beautifully uh when you seed the cells, you know, and then you sprinkle the drug, cells dead, all good. Uh, totally different issues when you start injecting something in the body, whether it's a mouse, a rat or or human. Well, you can't inject in the human before you inject in the mouse and the rat but anyway, so the big issue is how do you how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome? Uh, and the biggest question, I guess, you all know that it takes about 10 years to get something from the bench to to being somewhat approved. Not even fully approved, but somewhat approved. 10 years, uh, tens of millions, sometimes hundred millions of dollars. Just just something has to something has to be done about that. So, um, so we're here to to solve this problem today. ",
        "annotations": {
            "clarify goal": "Dr. Anna Moore is defining the objective of the discussion, which is to address the challenge of moving drugs from models to humans and the associated costs and timelines.",
            "identify gap": "She explicitly identifies gaps in the current process, notably the long timelines and high costs of drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yes. ",
        "annotations": {
            "supportive response": "The utterance 'Dr. Anna Moore: Yes.' is a minimal agreement or acknowledgment, fitting the definition of a supportive response as it expresses agreement without adding new content."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): So as a mechanistic scientist, I just want to to bring up this, you know, start at the base level basically, that the issue or one of the big issues that we have with this is that the con. ",
        "annotations": {
            "develop idea": "She is expanding on the discussion by bringing up a fundamental issue related to the challenges of moving drugs from models to humans.",
            "identify gap": "She mentions 'one of the big issues,' indicating a gap or problem in the current approach."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): of these processes or or you know, pathways, they're not even conserved between people, much less species. And so we have a really uh significant issue if we focus on one model organism and there's no confirmation of of pathways, molecular pathways for treatments. And so as you mentioned, something can be targeted in the mouse and never works in the human and doing research with model organisms, even closely related ones, I can tell you that even within the same order, there's no guarantee that these species have um kind of the same there's not the mechanistic processes aren't the same. So I think we need a lot more basic level research to really define what the conserved pathways that drive these processes of say EMT, cell migration, metastasis are, um before we can jump to treating humans and and we have to have both of those at the same time in my opinion. ",
        "annotations": {
            "identify gap": "The speaker recognizes a significant gap in knowledge about conserved pathways between species, which complicates the translation of research findings.",
            "develop idea": "The speaker expands on the idea that research findings in one species may not translate to another due to differences in pathways.",
            "clarify goal": "The speaker implies the goal of needing to understand conserved pathways to improve the translation of research to human treatments."
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Could I ask a follow up on on Crystal's comment? So I come from the optics and physics side so I'm just learning recently about the biological model making and so on. So how much do some of these relatively recent um 3D physiologically relevant cell culture models help? So so making basically um so so from you know, my reading and talking to some collaborators it seems like people are getting better at making in vitro models of of the human also for drug testing for example. So does that help maybe avoid some animal models or is that completely often brings along a whole other set of challenges? What's kind of the latest um state of the art there? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the use of 3D physiologically relevant cell culture models.",
            "acknowledge contribution": "The speaker acknowledges Crystal's previous comment before asking her question."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Are you talking like you know, like spheroid cultures and stuff? ",
        "annotations": {
            "ask question": "Dr. Anna Moore is seeking clarification on Lisa Poulikakos's mention of '3D physiologically relevant cell culture models,' specifically asking if she is referring to 'spheroid cultures and stuff?'"
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Mainly cell cultures that can reproduce for example also the extracellular environment. So so that are really physiologically relevant but in vitro. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an idea previously mentioned, providing more details about recent advancements in cell culture models.",
            "supportive response": "The speaker is providing additional information that supports and expands on the discussion."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It feels very promising, but my personal experiment experience uh recently collaborating with somebody doing a 3D organoid model. Um we got all kinds of interesting data in addition that I went to go validate with some metabolic imaging, just nothing alike. Not even slightly. And so then we just did all the experiments over again and it told a completely different story. It turned out that, you know, sitting in millimolar glucose, which is what you have to do for the cells to survive, completely wrecked their metabolism in terms of you know, what we're looking for. So it is really easy to get to be misled by those tools. I'm not saying they're bad, but it's very easy to get misled because then you think they're real, but something that's required for the culture conditions um ruins everything. And for someone who works in neuroimmunity, like the microglia that I focus on, they know when they're in culture. They know when they're being looked at and they change their their gene transcription. So those things have been have been very frustrating for for my personal kind of work. Now, they may work in other systems, but they they've never worked for me. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by sharing personal experiences and challenges faced with 3D organoid models.",
            "critical response": "The speaker is providing a critical perspective on 3D organoid models, highlighting their limitations and potential for misleading results."
        }
    },
    {
        "utterance": "Sixian You | MIT: I think there are some positive examples for uh breast cancer. So there is a research group in Wisconsin Medicine where they uh have these organoids from patients and they culture it and then they use therapy to uh you know, treat it and then using optical imaging technologies, they are able to see if they decrease or increase. Uh I have not been following up how well that really translates to the patient's recovery because of course that takes long time to track. Uh but maybe the sensitivity. I know neurons are a beast. They are different in every different environment. So maybe some models are more robust in different um scenarios and that's the thing we could take advantage of. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on an existing idea or concept, specifically discussing the use of organoids in cancer research.",
            "identify gap": "The speaker notes the challenge of tracking translation to patient recovery over a long period.",
            "offer feedback": "The speaker provides some insights based on their understanding of the topic."
        }
    },
    {
        "utterance": "Dylan Burnette: Yes, I would I would get I would agree with that. Not all organoids are the same. Uh there are some organoids that are much more robust and in vivo like such as the gut organoids are actually making real crips to feed the villi that have the the sites on them. And also the Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a previous statement.",
            "develop idea": "The speaker is elaborating on the concept of organoids, providing specific examples and insights."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous discussion about organoids by specifying his work on gut organoids.",
            "acknowledge contribution": "By referencing previous discussions on organoids, the speaker is acknowledging the contributions of others to the conversation."
        }
    },
    {
        "utterance": "Dylan Burnette: But that was metabolism. Yeah yeah yeah don't don't don't expect them to actually have the right metabolism. That's just that's a big ask. It's surviving and making similar cell types is what we're looking for here. Um that's why I think people we should we should lower our standard a little bit because to expect a something in a dish to be an in vivo environment is never going to happen. In vivo like we can probably get there. In vivo you got to go into an animal for that. ",
        "annotations": {
            "develop idea": "Dylan is expanding on the idea presented by previous speakers about the use of organoids in research, discussing their capabilities and limitations.",
            "signal expertise": "Dylan is sharing his experience and thoughts based on his research, which can be seen as signaling his expertise in the area.",
            "offer feedback": "He is offering feedback on how to approach research with organoids, suggesting to lower standards."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): I was going to mention the same paper. Although somebody commented that the mechanism of formation was different in vivo versus in the organoid, but that the function was similar. So I do think there are limitations. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by discussing the limitations and comparisons between in vivo and organoid models.",
            "supportive response": "The speaker is expressing agreement with a prior statement about the limitations of organoid models, validating the discussed concept."
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): But I think multi-disciplinary studies where you have people in vivo and you have organoids and then you are able to, I mean we can't study people, but you can do um patient specific therapeutics, right? So pulling cells or um or tumors out of patients to try to determine in their physiology if they can respond to these things. You kind of have to have all three because with without them you're you're running blind in some areas. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by suggesting a multi-disciplinary approach combining in vivo studies, organoid studies, and patient-specific therapeutics.",
            "identify gap": "The speaker highlights the limitation of not having a multi-disciplinary approach, stating that without it, researchers would be 'running blind in some areas'.",
            "supportive response": "The speaker is expressing agreement and validation for the combination of different research approaches."
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I think some of us are you can't study people though, right? Uh Molly, you study people, but what you get is not mechanistic per se. It's like a convolution of the mechanisms. And so there's got to be some I I I wish there is some translation between the mechanisms and the convolute the complex outputs of those mechanisms. And a lot of times that's things like blood flow because that's something you can see or biomarkers that are accessible, structural changes, um liquid biopsies, things like that that give you hints as to what the mechanism might be. But um so far uh those things have not been enough to give you a a strong inference of the mechanisms that are so have been so painstakingly acquired in in model systems. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea that there's a need for translation between mechanisms found in model systems and human studies.",
            "identify gap": "The speaker identifies a gap in the current ability to translate mechanisms from model systems to human studies."
        }
    },
    {
        "utterance": "Dylan Burnette: My lab's cheating a little bit. We are not looking at small molecules, we're looking at drugs. So we're trying to repurpose FDA approved drugs because I don't really develop drugs. Uh so that's that that's how we're skirting around this issue of like you develop a small molecule that's very effective in in vitro, you go into a patient doesn't it doesn't partition correctly in the body. What the heck's no, after 10 years of work, that's annoying. So we are we are we're cheating a little bit by uh just focusing right now on repurposing FDA approved drugs that have a huge literature. So the mechanism has been delved into in vitro, in animal models and in humans as much as we can. So um there's a way around that. Now, not every problem can, you know, uh we can't pull an FDA approved drug off the shelf for every single problem. That's not going to be feasible, but there's a good handful I think we can. ",
        "annotations": {
            "develop idea": "Dylan is expanding on his lab's approach to drug development, providing reasons and context.",
            "offer feedback": "Dylan provides insights from his experience, which can be seen as offering feedback on the drug development process.",
            "express humor": "Dylan uses a humorous tone when discussing the frustrations of drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, so one of the issues is uh like I said before, is delivery and imaging that delivery. And I know that there's a maybe handful of drugs that allow for that. In fact, if I start scratching my head and trying to name one, I probably wouldn't be able to. Uh there's something on the pet side that's available, I think, but nowhere else. Do you think that this is a an important issue to be able to to see what you're delivering and where? ",
        "annotations": {
            "identify gap": "Highlighting the limitation in current drug delivery methods and the ability to image them.",
            "ask question": "Dr. Moore asks for opinions on the importance of being able to see what is being delivered and where.",
            "encourage participation": "Asking for opinions, which encourages participation."
        }
    },
    {
        "utterance": "mark sellmyer: I I can I can try to uh comment on that. I mean, I think the oldest uh sort of theranostic, maybe radioactive iodine for thyroid cancer. Because there you're getting a beta emission, which is killing the actual tumor and then or the thyroid in general and then you're also getting the uh gamma emission that you can detect with the camera. And so, um in my group, um you know, we've been interested in in uh well there's quite a there's quite a lot of efforts out there that are along these lines, especially the nanoparticle community, which can label, you know, things with both therapeutics and diagnostics. My group is stuck on the concept of uh reporter genes. And because GFP's been so critical to, you know, microscopy and biomedical applications and and study, you know, if we could develop good reporter genes for in vivo and human applications, that seems critically important to look at like living drug therapies. So cells that are being regenerative medicine for your cardiac myocytes or um you know, uh car T cells are a modern example, um virally delivered vectors another another example. And so, you know, to me on that front, if you can if you can image the delivery of these types of therapeutics that have different PK because they are tend to um sense and respond to pathology, that makes it a totally different problem than just what the admin characteristics are of a of uh chemotherapy or a biologic. So I think I think the idea is is ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of theranostics and reporter genes, providing examples and explanations.",
            "propose new idea": "The speaker discusses the application of reporter genes in in vivo and human applications, which could be seen as proposing a new approach."
        }
    },
    {
        "utterance": "mark sellmyer: is really important and how do we develop things that are able to sense drug delivery. There's also the idea um from pet because I do pet on some of my day job that you can radio label the drug itself or something that's going to um show you whether or not you're inhibiting with therapeutic doses. So example of this is the estrogen receptor um and people have made drugs like full vestrant which are estrogen receptor degrader. So that drug binds to the estrogen receptor and it's got a hydrophobic group on it that targets the whole receptor to be degraded. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on existing concepts related to drug delivery and imaging by providing specific examples and explanations.",
            "offer feedback": "The speaker is also providing a suggestion for how to approach the problem of sensing drug delivery, which can be seen as a form of feedback."
        }
    },
    {
        "utterance": "mark sellmyer: Now if you make a estrogen receptor estradiol 4 and 18 probe, then you can use that to monitor the success of your estrogen receptor degrader in people. And so um people have have done this and it's becoming part of the standard of of drug development is try to try to develop companion diagnostic agents that are going to let you look at drug delivery and I'll stop. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on existing ideas about drug development and monitoring, providing a specific approach for monitoring drug success.",
            "Offer feedback": "The speaker provides a specific suggestion for how to monitor drug delivery, using a probe to monitor the success of estrogen receptor degraders.",
            "Supportive response": "The speaker expresses a positive view on developing companion diagnostic agents, indicating it's becoming part of the standard of drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, not not only drug delivery but also the the target engagement and dis disappearance of the target if that's the if that's the goal. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous thoughts about drug delivery and imaging, specifically highlighting the importance of target engagement.",
            "offer feedback": "Dr. Moore is providing feedback on what aspects are important (target engagement and disappearance).",
            "clarify goal": "The utterance aids in clarifying the objectives of their work, highlighting the need to focus on drug delivery, target engagement, and target disappearance."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um so so the word nano has been said several times. So um I I would like you guys to uh to give some thoughts about the future of nanotechnology in that regard. Um those of you who work in that area maybe want to speak a little bit. ",
        "annotations": {
            "ask question": "The speaker requests information about the future of nanotechnology.",
            "encourage participation": "The speaker invites group members, especially those working in the area, to share their thoughts."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, before can I comment on that? So before going to nanotechnology, I just wanted to add one more thing and it's that like the problems of the in vitro make sense from different angles when you look at it. I mean from the like the biological point of view, it makes perfect sense that they don't basically recapitulate what happens in vivo. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes the limitation of in vitro models in recapitulating what happens in vivo, highlighting a gap in current research approaches."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: But like from the physical point of view, it would be another story like different organs have different stiffness. They have like different properties and all of those things needs also to be considered in the in vitro setting. Like with the advances in the 3D bioprinting and like making like um uh pattern substrates that can basically provide opportunity for cells to basically make a 3D structures rather than like the flat surface uh 2D structured, all of those can be of a great help for getting more meaningful and robust in vitro data. So I think for that purpose maybe a group of scientists that have different looks into the same problem needs to collaborate to each other to basically make a perfect in vitro like setting that can be more close to the in vivo part. ",
        "annotations": {
            "propose new idea": "Morteza suggests using 3D bioprinting and pattern substrates as new approaches to improve in vitro settings.",
            "identify gap": "Morteza points out the gap in current in vitro settings, specifically that they do not account for the different physical properties of organs.",
            "encourage participation": "Morteza emphasizes the need for collaboration among scientists with different expertise to create better in vitro settings."
        }
    },
    {
        "utterance": "mark sellmyer: I'll just say on that that frame too like it's not only to just do the study if you could or study basic biology, if you can start making better 3D culture systems and start to grow organs, there's also huge biomedical applications and treatments that can come out of it. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using 3D culture systems for biomedical applications and treatments.",
            "supportive response": "The speaker is expressing a positive view on the potential of 3D culture systems.",
            "offer feedback": "The speaker is providing a suggestion or idea for future research."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, exactly. These are basically the concept of the lab on a chip which basically again it's a kind of multidisciplinary thing. And for the nanotechnology, I mean, we are working in the field of nanomedicine for a couple of years and like one of the main problems that we have for delivery and also for like using them as a contrast agent is their interactions with biological systems. ",
        "annotations": {
            "signal expertise": "The speaker mentions working in the field of nanomedicine for a couple of years, indicating their expertise.",
            "identify gap": "The speaker identifies a main problem with delivery and interactions with biological systems in nanomedicine.",
            "supportive response": "The speaker's discussion contributes to and supports the ongoing conversation about challenges in nanomedicine."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: So what happens is that what we makes in like laboratories are totally different from what we see like when they interact with the plasma proteins or any type of biological fluids. So what happens is that different types of biomolecules comes to the surface of nanoparticles and interact with them and basically form a corona around the surface of nanoparticles. So based on the type of the proteins, amount of the proteins, conformational changes of the proteins, basically we have totally different fate for the nanoparticles. So it can affect imaging, it can affect targeting, it can affect safety of the nanoparticles and those things basically needs to be considered in the imaging like procedures because you can imagine when you have additional layer at the surface of like nanoparticles, if you use that nanoparticles as a carrier, so what happens is that they can affect drug release. ",
        "annotations": {
            "signal expertise": "The speaker demonstrates expertise in nanotechnology and its applications in biological systems.",
            "develop idea": "The speaker elaborates on the interaction of nanoparticles with biological systems and its implications.",
            "clarify goal": "The discussion clarifies challenges and goals in applying nanotechnology to overcome biological barriers."
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Or if you have like a fluorophore or something like that and what happens is that we may have like some unwanted interactions with those like labeling species that can affect the like the imaging capacity. So from a nanotechnology perspective, I would say we need more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles. ",
        "annotations": {
            "code name": "explanation",
            "another code": "another explanation"
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So maybe also to follow up on Morteza's point um so in my research I focus a little bit more on using nanotechnology to manipulate the light. ",
        "annotations": {
            "code name": "Develop idea",
            "explanation": "The speaker slightly expands on the topic of nanotechnology in relation to her research."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So I think there is there's the whole field of you know, having nanoparticles in the body and and Morteza really nicely outlined also several of the challenges that come with that. Um and I think some of uh you know, what I think is kind of a new direction in using nanotechnology is actually um not necessarily having it interact directly in the body but having it manipulate the light with which you illuminate uh the part the biological species you want to see and actually then using light itself as a marker. ",
        "annotations": {
            "propose new idea": "The speaker proposes a new direction for using nanotechnology to manipulate light with which biological species are illuminated.",
            "acknowledge contribution": "The speaker acknowledges Morteza's contribution about outlining challenges of using nanoparticles in the body."
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: Um and some of the things I I'd also love to get people's perspective on there is um for example also as Morteza was saying, there are new ways where you can better um model the tissue in three dimensions and actually get effects such as the extracellular matrix um and and for instance in breast cancer metastasis, the extracellular matrix actually plays a really critical role. So um I'm curious to know how do people image that today because I think using sophisticated nano optics it would be potentially possible to monitor that. ",
        "annotations": {
            "ask question": "The speaker asks for people's perspective on how to image the extracellular matrix, seeking information on current methods.",
            "acknowledge contribution": "The speaker references Morteza's mention of new ways to model tissue in 3D.",
            "encourage participation": "The speaker invites others to share their perspectives on using nano optics for imaging."
        }
    },
    {
        "utterance": "mark sellmyer: It's a great question how to image the matrix. There aren't great tools as I understand. Maybe someone else knows. I think there's some MR techniques and someone MR might be Molly can jump in and correct me but I think there are ways to look at like higher how hyaluronic acid or you know, things that are around but I I don't know too much that's um specific to ECM like imaging collagen. I mean, I guess the other other techniques that come to mind are like MR elastography that's like Yeah and and ultrasound sort of stiffness measurements. ",
        "annotations": {
            "ask question": "The speaker asks how to image the matrix, seeking information or clarification.",
            "propose new idea": "The speaker suggests potential methods for imaging the matrix, including MR techniques, MR elastography, and ultrasound."
        }
    },
    {
        "utterance": "mark sellmyer: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "mark sellmyer: Just some extent you oh go ahead. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Talk to me. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute or share their thoughts, indicated by 'Talk to me.'"
        }
    },
    {
        "utterance": "Dr. Anna Moore: I was just going to say that, you know, perfusion and diffusion imaging goes this it's in the same category. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by suggesting perfusion and diffusion imaging belong in the same category as something previously discussed.",
            "supportive response": "The speaker is contributing to the discussion in a way that supports or builds upon previous ideas without adding new content or being critical."
        }
    },
    {
        "utterance": "Benjamin Bartelle, ASU: Well, to some extent you can use MRscopy. Um people have picked up hyaluronic acid that way, but it's only for things that are highly um highly present there. So what is the signaling space of the ECM, what kind of cytokines have been decorating the ECM, all that stuff is kind of beyond the reach of clinical imaging without a biopsy. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about imaging techniques, specifically mentioning MRscopy and its limitations in detecting certain ECM components.",
            "ask question": "The speaker poses rhetorical questions about the signaling space of the ECM and cytokines decorating it, indicating a search for further information or discussion.",
            "identify gap": "The speaker explicitly notes that certain aspects of the ECM are beyond the reach of clinical imaging without a biopsy, highlighting a gap in current capabilities."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, lactate. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous mention of lactate."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "mark sellmyer: Yeah, I mean, I I think like as a big field a big wide open blue ocean of research really is the extracellular space because we know so much about cell biology, but like we don't really even know what happens to proteins very well once they get in the extracellular space, especially in the animal. So uh and it's very it's a challenging field, right? Because it's hard to um model that in in as we got this comes full circle back to the culture conditions question. ",
        "annotations": {
            "identify gap": "The speaker highlights a significant gap in knowledge regarding protein behavior in the extracellular space.",
            "develop idea": "The speaker expands on the challenges and complexities of researching the extracellular space.",
            "ask question": "The speaker implicitly asks about the challenges in modeling the extracellular space in vitro."
        }
    },
    {
        "utterance": "mark sellmyer: Tough. ",
        "annotations": {
            "critical response": "expresses a challenge"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, so I I think that uh at the end of this um at the end of the session we will need to produce some ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: ideas and some hard pressing questions, uh what is on the way from translating things um from models to humans. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the direction of the discussion, focusing on the goal of translating findings from models to humans."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um in in all those various areas, not just, you know, drug delivery but just imaging. Even translating imaging agents uh that also requires some jumping through the loops. ",
        "annotations": {
            "summarize conversation": "The utterance summarizes the areas of discussion, specifically highlighting drug delivery and imaging.",
            "identify gap": "The utterance implicitly recognizes the challenges or gaps in translating research from models to humans."
        }
    },
    {
        "utterance": "Sixian You | MIT: Yeah, I'm really curious to know like um why why it takes 10 years, this is a very naive question. Why it takes 10 years to develop drugs and uh why it takes uh thousands of millions. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on why it takes 10 years and thousands of millions of dollars to develop drugs."
        }
    },
    {
        "utterance": "mark sellmyer: I guess how much clinicians get paid, it's uh, you know. ",
        "annotations": {
            "critical response": "The speaker is implying a critique of the drug development process, suggesting that clinicians' pay might be a factor in the high costs and lengthy timelines.",
            "express humor": "The utterance includes a casual, speculative tone that could be interpreted as slightly humorous or sarcastic."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. Sorry guys, it's a big part of it. ",
        "annotations": {
            "None": "No relevant code explicitly applies to this utterance"
        }
    },
    {
        "utterance": "mark sellmyer: As the as the clinician on the call, I can't defend anything here, but I guess the um, the the thing that strikes me is is the sheer just amount of research that needs to go in to validate safety and the amount of time that that takes and effort. ",
        "annotations": {
            "signal expertise": "The speaker mentions being a clinician on the call, signaling their expertise.",
            "identify gap": "The speaker recognizes the need for a significant amount of research to validate safety, indicating an awareness of a gap."
        }
    },
    {
        "utterance": "mark sellmyer: And then doing, you know, to get something to as an imaging probe, it's actually frankly somewhat markedly easier to get into the clinic than it is for a therapeutic where imaging probes generally are benign, right? They're not going to kill you, a radio tracer is low, MR contrast agents may be harder. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the differences between imaging probes and therapeutics in terms of getting them approved for clinical use.",
            "Signal expertise": "The speaker demonstrates familiarity with the process of drug and imaging agent development."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Somehow we've convinced people of this. Yeah, it's amazing. But yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing another group member's input.",
            "supportive response": "The speaker is expressing agreement or validation for the previous statement."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, yeah, because, you know, radio tracer, you inject them in such a small, small quantity that, you know, it's. ",
        "annotations": {
            "supportive response": "Dr. Anna Moore is showing agreement or understanding with the previous discussion.",
            "develop idea": "She is providing more information about radio tracers, elaborating on their characteristics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh yeah, I'm talking about Gadolinium. That's just. ",
        "annotations": {
            "supportive response": "Benjamin is confirming the topic of discussion, showing agreement or acknowledgment of the previous mention of Gadolinium."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, Gadolinium. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous mention of Gadolinium, showing recognition of the topic or substance discussed."
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's some reason it's okay to put in millimolar amounts of Gadolinium into a person. ",
        "annotations": {
            "critical response": "The speaker is expressing surprise or criticism about the use of millimolar amounts of Gadolinium in humans, implying a concern or negative evaluation of current practices."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, there's a warning on the label. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: The debate the debate rages, yeah. ",
        "annotations": {
            "express humor": "Benjamin makes a light, humorous comment about the ongoing debate regarding Gadolinium."
        }
    },
    {
        "utterance": "mark sellmyer: But but I think, you know, the therapeutic index for a therapy is a huge deal, right? If you you don't want to be causing toxicity and in the realm of do no harm, right? It it just takes us. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the challenges of therapy development by highlighting the importance of the therapeutic index.",
            "supportive response": "The speaker is providing a supportive comment to the discussion by emphasizing a critical aspect of therapy development."
        }
    },
    {
        "utterance": "mark sellmyer: So so Sian, I I I don't know how to answer the question other than to say like as imagers, we actually are in a better position of um, getting things translated. ",
        "annotations": {
            "supportive response": "The speaker provides a response that acknowledges the complexity of drug development and offers a perspective on the role of imagers, which can be seen as somewhat supportive.",
            "develop idea": "The speaker is contributing to the discussion by providing his viewpoint on drug development and translation, building on the prior context."
        }
    },
    {
        "utterance": "mark sellmyer: So like, you know, this was there's image guided therapies being here. People have developed fluorescent probes to thing like folate receptor or looking at um ICG for various lung cancers. So people have taken, you know, molecular imaging approaches and put those into patients without a huge, you know, long, long time to get those um, we're talking years rather than 10 years maybe to do this. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the concept of image-guided therapies and their development.",
            "signal expertise": "The speaker is showing expertise in the field of image-guided therapies and molecular imaging.",
            "clarify goal": "The speaker is discussing the objectives and achievements in the field of image-guided therapies."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, but you know, answering your question uh Sian is um, you know, just just look at the catalog from uh Charles River, you know, how much you pay for a transgenic animal. You know, it's like 250 bucks for one mouse. ",
        "annotations": {
            "develop idea": "Dr. Anna Moore is expanding on the idea that drug development is costly and time-consuming by providing a concrete example of the cost of transgenic animals.",
            "supportive response": "While providing information, her response also serves to support the ongoing discussion about drug development costs, though it's more about adding content than expressing agreement."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's a deal. ",
        "annotations": {
            "supportive response": "Benjamin Bartelle expresses agreement or acknowledgment with Dr. Anna Moore's comment about the cost of transgenic animals, showing a positive sentiment."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We transgenic GQ animals, 400 bucks anyway. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: I know. I'm with you, I'm with you. I know. And yeah, those are even higher. And then you need n equals more than three, right? To do anything, you know, anything meaningful. And then um, all the antibodies and everything, and then once you're done with the with the with the pre-clinical studies in your lab. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas by mentioning specific challenges like the number of samples needed and the cost of antibodies.",
            "identify gap": "The speaker is implicitly identifying gaps in the current research process, such as the need for more meaningful data and the high costs involved.",
            "supportive response": "The speaker is expressing agreement and validation for previous comments."
        }
    },
    {
        "utterance": "Dr. Anna Moore: You go to CROs, uh, which are contract research organizations to do tox, to do PKPD, that's all required by FDA. And I hate to show you the bills from those companies because I went through that with my uh, with the compound that we're developed. You just, you know, basically wondering, you know, how can you possibly pay for all that? So, and then, uh, the companies that, you know, they invest money in this and then they want to recover those money and then we're wondering why the drugs are so expensive because if so much money you want to recover it somehow, right? ",
        "annotations": {
            "develop idea": "Dr. Moore is expanding on the challenges of drug development, specifically the financial aspects and involvement with CROs.",
            "identify gap": "The utterance highlights the inefficiencies and high costs in the drug development process as a gap.",
            "summarize conversation": "Dr. Moore is summarizing aspects of the drug development process and its challenges, particularly from her experience."
        }
    },
    {
        "utterance": "Benjamin Bartelle: There's a ray of light. ",
        "annotations": {
            "None": "No relevant code strictly applies to this utterance based on the provided definitions."
        }
    },
    {
        "utterance": "Benjamin Bartelle: And that this builds on something Dylan brought up earlier is um, you were saying you're using clinically approved drugs in your your studies and that sort of gives you a shortcut, right? With the 90% of investment in new medicines is in biologic drugs. Most of these are antibody based drugs, right? And they're going after specific targets. ",
        "annotations": {
            "develop idea": "The speaker expands on Dylan's idea about using clinically approved drugs.",
            "acknowledge contribution": "The speaker acknowledges Dylan's previous idea.",
            "supportive response": "The speaker supports and builds upon Dylan's idea.",
            "offer feedback": "The speaker provides feedback on the use of clinically approved drugs."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Like I made an antibody against this target, antibody against that target, I've proved that it's focal enough where it doesn't cause the worst side effects. Because of the modularity of nanotechnology and biological systems, the what everyone is doing right now, at least in the synthetic biology space, is they're starting with that. like we know this biologic drug hits this target safely. And so now we're going to build a car T cell therapy around that biologic drug. ",
        "annotations": {
            "propose new idea": "The speaker introduces the approach of using known biologic drugs to develop new therapies like car T cell therapy.",
            "develop idea": "The speaker elaborates on this approach by explaining how it works, including the use of antibodies against specific targets and building new therapies around existing drugs."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We know that this drug goes hits T cells specifically. Great, we're building a theragnostic that's going to find the T cells and report back to us that it's done a job in it. So we have there is a way of bypassing some of that initial safety testing if you do go with these um biologics or just antibodies that are already approved. So there there's some hope there and I think the as we get better and better at this, we may start building out something like a grass list, you know, it's like generally recognized as safe list. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive view on the approach, indicating hope and optimism about its potential."
        }
    },
    {
        "utterance": "mark sellmyer: Good points. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and validation of other group members' contributions without adding new content."
        }
    },
    {
        "utterance": "Dr. Anna Moore: But but I'm still wondering if, you know, wouldn't it be great if every single drug that you uh inject has somewhat some kind of an image image guided guidance image guiding properties. So you can monitor this drug. ",
        "annotations": {
            "propose new idea": "The speaker suggests incorporating image-guided properties into drugs for better monitoring, which can be seen as introducing a new approach to drug development."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, without sacrificing, you know, many, many animals. And avoiding those costly studies that you have to pay for because you can actually do it yourself. ",
        "annotations": {
            "supportive response": "The speaker is expressing support for the idea of reducing animal testing and costly studies.",
            "develop idea": "The speaker is elaborating on the benefits of an idea previously discussed."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Because you can get quantitative data. ",
        "annotations": {
            "supportive response": "The utterance provides a positive view on the value of quantitative data in drug development, supporting the discussion on the benefits of imaging."
        }
    },
    {
        "utterance": "Sixian You: So what I'm hearing is that uh, so for therapies, the major barrier is actually in biology is in in the therapies. ",
        "annotations": {
            "summarize conversation": "The speaker is attempting to summarize or reflect on the discussion about the major barrier in therapies, trying to understand the main point."
        }
    },
    {
        "utterance": "Sixian You: It's not image guiding technologies. But if we want to develop image guiding technologies, it will be helpful to develop something that can monitor these early changes induced by the drugs. ",
        "annotations": {
            "propose new idea": "The speaker suggests developing capabilities to monitor early changes induced by drugs as a way to advance image-guided technologies.",
            "develop idea": "The utterance builds upon the existing discussion about drug development challenges and the potential of image-guided technologies by highlighting the need for monitoring capabilities."
        }
    },
    {
        "utterance": "Sixian You: So either is the delivery of the. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: With companion diagnostics. ",
        "annotations": {
            "develop idea": "The utterance contributes to the development of the idea by mentioning companion diagnostics as a means to monitor or assess therapies.",
            "supportive response": "The utterance is supportive as it adds to and builds upon previous discussion ideas."
        }
    },
    {
        "utterance": "Sixian You: Companion diagnostics. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or alignment with the concept of companion diagnostics, which was discussed as a potential solution for monitoring drug delivery and effects."
        }
    },
    {
        "utterance": "Molly Bright: Can I weigh in on a completely different take on on I guess yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Molly Bright: So I think about it from the other end and I guess I'm surrounded by very long-term treatments and also ambiguous treatments. So there are so many therapeutics and drugs that we use in humans that may or may not work for someone, we don't know how to dose it and we don't have an imaging marker of what it's doing particularly in the brain. ",
        "annotations": {
            "identify gap": "Molly recognizes gaps in current therapeutic approaches, specifically the lack of effectiveness for individuals, dosing guidance, and imaging markers.",
            "develop idea": "Molly expands on the challenges and implications of current therapeutic practices, highlighting the need for better solutions."
        }
    },
    {
        "utterance": "Molly Bright: Um, so that's that's my domain would be the brain, that's unfortunately what I can focus on. But there are so many drugs that I think sit into this category and if you think of all of the mood disorders and anything to do with mental health, anything to do with long-term degeneration of neural function uh and and dementia. ",
        "annotations": {
            "develop idea": "Molly is expanding on the conversation by sharing her perspective on drugs that fit into a certain category, related to her expertise in the brain.",
            "signal expertise": "Molly explicitly states her area of expertise as the brain.",
            "identify gap": "Molly implies a gap in knowledge or treatment for certain conditions such as mood disorders, mental health issues, and long-term degeneration of neural function including dementia."
        }
    },
    {
        "utterance": "Molly Bright: We need a time scale of looking at. ",
        "annotations": {
            "identify gap": "The speaker is highlighting the need for considering a time scale, implying a gap in their current approach or understanding."
        }
    },
    {
        "utterance": "Molly Bright: What a drug does and what happens in the absence of that drug in the face of huge human variability to evaluate if we're remotely close to getting after what we're after. ",
        "annotations": {
            "clarify goal": "The utterance comments on the goal of evaluating if we're remotely close to getting after what we're after in terms of drug effectiveness.",
            "identify gap": "The utterance highlights the gap in understanding how drugs work in the face of huge human variability.",
            "develop idea": "The utterance builds upon the previous discussion about drug development and its challenges."
        }
    },
    {
        "utterance": "Molly Bright: And that is a huge cost. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Molly Bright: Sorry, downer. ",
        "annotations": {
            "Express humor": "The speaker attempts to use humor to address the conversation's tone.",
            "Critical response": "The speaker expresses a negative evaluation of the conversation's direction or tone."
        }
    },
    {
        "utterance": "mark sellmyer: Well, I don't know. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "mark sellmyer: Is hyperpolarized a way forwards to look at function in the brain using hyperpolarized substrates with MRI? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the use of hyperpolarized substrates with MRI for studying brain function."
        }
    },
    {
        "utterance": "Molly Bright: Is that really going to get at the. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on a prior statement or idea proposed by another group member."
        }
    },
    {
        "utterance": "Molly Bright: The limitation of this scale of treatment efficacy? Yeah. ",
        "annotations": {
            "ask question": "Molly Bright is questioning the limitation of the current scale of treatment efficacy."
        }
    },
    {
        "utterance": "mark sellmyer: Right. So so efficacy as measured by some um, for psychiatric disease. ",
        "annotations": {
            "identify gap": "The speaker points out the difficulty in measuring efficacy for psychiatric diseases, indicating a gap in current capabilities.",
            "supportive response": "The statement agrees or aligns with previous discussions, showing support."
        }
    },
    {
        "utterance": "mark sellmyer: Really hard to measure, well, harder to measure than let's say a tumor size, you know. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the challenges of measuring treatment efficacy, comparing psychiatric diseases to conditions like cancer.",
            "supportive response": "The speaker's comment supports the discussion on the difficulties of measuring treatment effects, especially in psychiatric diseases."
        }
    },
    {
        "utterance": "Benjamin Bartelle: almost worse that we have the wrong. ",
        "annotations": {
            "critical response": "The speaker is expressing a critique or concern about the current state of affairs, implying that having the wrong approach or information might be worse than not having any.",
            "identify gap": "The speaker's statement might also imply a recognition of a gap or problem in the current approaches or understanding."
        }
    },
    {
        "utterance": "Benjamin Bartelle: metrics, right? Like Biogen Idec just spent a billion dollars on this drug that reduces Alzheimer's plaques and it worked in mice and it works in people. It reduces the Alzheimer's plaque, doesn't do anything else. You still have Alzheimer's, you just don't see the plaques as bad anymore. And so they're image guided biomar, their imaging biomarker was absolutely wrong and they were completely all in on it and they're still trying to get it to work. So so you can really get led astray with these things, yeah. ",
        "annotations": {
            "Critical response": "The speaker criticizes the approach of using imaging biomarkers without efficacy, citing Biogen Idec's experience with an Alzheimer's drug.",
            "Offer feedback": "The speaker provides feedback on the limitations and potential misdirection of using imaging biomarkers in drug development."
        }
    },
    {
        "utterance": "Molly Bright: Any anything positive to say in this direction to balance what I've done to the conversation? ",
        "annotations": {
            "ask question": "Molly Bright is requesting information or perspectives from others to balance her previous contribution.",
            "encourage participation": "Molly Bright is inviting others to contribute their thoughts, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's a world of opportunity. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive evaluation of the situation, providing encouragement and acknowledging opportunities."
        }
    },
    {
        "utterance": "Lisa Poulikakos: understanding. So maybe on Ben's point. So basically this drug reduced the plaques in Alzheimer's and in mice it also reduced symptoms but in humans it didn't reduce symptoms. Is that correct? ",
        "annotations": {
            "ask question": "Requesting confirmation or clarification on a prior statement or idea proposed by another group member.",
            "develop idea": "expanding, building upon, or elaborating existing ideas through reasoning, examples, clarification, and evidence.",
            "acknowledge contribution": "verbally recognizes another group member's input, but not agreeing or expanding."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. That's Aducanumab is the story there. ",
        "annotations": {
            "Acknowledge Contribution": "The speaker is recognizing a prior statement about Aducanumab.",
            "Supportive Response": "The speaker is expressing agreement with the previous discussion."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Okay, interesting. And does are there any ideas why or it's completely unknown? ",
        "annotations": {
            "ask question": "The speaker is requesting information or ideas about why a drug worked in mice but not in humans."
        }
    },
    {
        "utterance": "Benjamin Bartelle: The the amyloid hypothesis um was you know super popular this gets back to Crystal's original point, which is uh people get hung up stuck on these mechanisms and they seem to be what you're after and in mice these amyloid plaques removal of the amyloid plaques was highly correlated with the um positive outcomes in these Alzheimer's models. We don't know if the Alzheimer's models are accurate. We don't know if Alzheimer's plaques that you see are anyway like related directly to Alzheimer's in humans. Uh human patients often have Alzheimer's plaques. They often have Alzheimer's plaques and no Alzheimer's. They sometimes have no plaques and Alzheimer's. So it was enough it was enough to go on where the animals model animal models worked. So it was worth pursuing because they were getting good data here and they could see their imaging biomarker in humans work. But it turned out or ",
        "annotations": {
            "develop idea": "Benjamin is expanding on Crystal's idea about mechanisms and providing examples from Alzheimer's research.",
            "identify gap": "Benjamin identifies gaps in understanding between mouse models and human Alzheimer's disease.",
            "critical response": "Benjamin is questioning the amyloid hypothesis and its translation from mice to humans.",
            "offer feedback": "Benjamin provides feedback on the limitations of current research approaches."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "supportive response": "The speaker expresses surprise and acknowledgment of a prior statement, showing engagement with the conversation.",
            "express humor": "The utterance can also be seen as expressing a form of humor or astonishment at the unexpected outcome described."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I mean the case is still they're still making their case. There's their other companies based on the same amyloid hypothesis still testing the same thing. There may be some condition where it works but as yet it it does not work. So ",
        "annotations": {
            "develop idea": "The speaker discusses and builds upon the existing idea of the amyloid hypothesis and its implications.",
            "supportive response": "The speaker acknowledges the ongoing efforts based on the amyloid hypothesis in a neutral manner."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "critical response": "The utterance expresses surprise or skepticism towards the information provided, questioning the implications of Benjamin Bartelle's narrative about the drug reducing Alzheimer's plaques but not symptoms."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Where did they go wrong? Did they go wrong in dish where they saw these amyloid plaques and got completely locked in on it? Did they go wrong in their animal models? Is that actually relevant to mice where the plaques are important for mice and cured them? Or is there something else going on in humans where we're just not seeing that part? Like we're getting half of it. You have it's maybe it's necessary but not sufficient. We don't know any of that stuff yet just because the human work is so slow and the one molecular marker we spent so much time on, you know these great pet tracers for Alzheimer's plaques. ",
        "annotations": {
            "ask question": "The speaker is asking questions about where the approach to developing Alzheimer's drugs went wrong.",
            "offer feedback": "The speaker is providing feedback on the current state of Alzheimer's drug development, specifically regarding the focus on amyloid plaques.",
            "identify gap": "The speaker is highlighting gaps in understanding, such as the relevance of animal models and in vitro experiments to human disease mechanisms."
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. Why? Oh, that's yeah, amazing. ",
        "annotations": {
            "ask question": "The speaker requests information with 'Why?'",
            "supportive response": "The speaker expresses a positive evaluation with 'Oh, that's yeah, amazing.'"
        }
    },
    {
        "utterance": "Molly Bright: I I mean maybe one way to distill one of these issues is the time scale of knowing efficacy in humans is way too long. Um I don't know how like is there a way to work backwards? I I'm I'm not sure. Um but to to always go from small to big could mean that an entire direction is not wasted but mistargeted. ",
        "annotations": {
            "ask question": "Molly asks if there's a way to work backwards.",
            "identify gap": "Molly points out the issue with the time scale for efficacy in humans and potential for mistargeted research directions.",
            "critical response": "Molly critiques the current approach by suggesting it could lead to mistargeted directions."
        }
    },
    {
        "utterance": "Benjamin Bartelle: What if the mechanism for Alzheimer's the disease progression in Alzheimer's in human beings has never actually been seen because you can't recapitulate it in a dish and you can't recapitulate it in a mouse. I don't I don't know but what if that's true then everything we're doing is wrong in Alzheimer's. And as yet there are no there are no root cause treatments for any neurodegeneration and maybe it's because we're not seeing it because we're not looking in the right place. It's possible. A world of opportunity. ",
        "annotations": {
            "propose new idea": "The speaker introduces a hypothetical scenario questioning current Alzheimer's research methodologies.",
            "identify gap": "The speaker highlights the gap in understanding Alzheimer's disease mechanisms and the lack of effective treatments.",
            "critical response": "The speaker critically evaluates current approaches to Alzheimer's research."
        }
    },
    {
        "utterance": "Molly Bright: We'll always have a job. Um but it's ",
        "annotations": {
            "express humor": "The speaker makes a light-hearted comment about their job security, which can be interpreted as an expression of humor."
        }
    },
    {
        "utterance": "Mark Sellmyer: Molly, I think your question is good about time scales, right? And the the very last question of our group 2.3 topic is can we integrate imaging across time to see the impact of a previous dosing over weeks to months or can you integrate, you know, biologic processes over time to capture something that might be a longer um longer in the making and longer in the resolution. It's tough. ",
        "annotations": {
            "ask question": "The speaker poses a question about integrating imaging across time.",
            "develop idea": "The speaker builds upon previous comments by exploring the concept of integrating imaging over time.",
            "supportive response": "The speaker expresses agreement and validation of another group member's contribution.",
            "encourage participation": "The speaker asks a question that invites further discussion and participation."
        }
    },
    {
        "utterance": "Crystal Rogers: There are people doing primate research to do exactly this, right? So there was a whole session that the ORIP had about the importance of primate research, which again still isn't the same, but at least it scales up to um to us as primates. But I think that is the same it's the same thing again, right? Super expensive, very time consuming, still not exactly the same physiology and there's no guarantee that it will directly translate to humans. So so I don't know what I said. I don't think I added anything, but I just wanted to bring that up again that it we do have a way to test um it's just it's not efficient and it's super hard. ",
        "annotations": {
            "identify gap": "Highlighting the limitations and challenges of primate research, including cost, time, and translatability issues.",
            "critical response": "Questioning the efficiency and effectiveness of primate research."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Millions of dollars going into marmosets for this exact reason of like maybe if mice don't tell us, maybe marmosets will. Millions being invested. Every every big neuroscience lab in America is is putting together their marmoset program in the hopes that it's going to be relevant. ",
        "annotations": {
            "process management": "The speaker discusses the investment of millions of dollars into marmoset research as an alternative to mice models, highlighting the scale of research efforts."
        }
    },
    {
        "utterance": "Mark Sellmyer: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the potential applications or developments of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "supportive response": "Expressing agreement or validation for the idea of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. It seemed impossible 10 years ago, but now with I mean everyone's everyone's getting into a cell based therapy and what do you how are you going to track those things? ",
        "annotations": {
            "ask question": "The speaker is asking for information on how to track cell-based therapies.",
            "identify gap": "The speaker implies a gap in current capabilities regarding tracking cell-based therapies."
        }
    },
    {
        "utterance": "Dylan Burnette: But what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. So so when Crystal was talking I was like, Yeah. ",
        "annotations": {
            "signal expertise": "The speaker expresses his viewpoint as a scientist, highlighting his perspective on science communication.",
            "identify gap": "The speaker identifies a gap in communication between scientists and the general public.",
            "critical response": "The utterance has a critical tone towards the current state of science communication."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "ask question": "The speaker is requesting information or opinions about the future of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement or validation for the idea of genetic reporters in human beings."
        }
    },
    {
        "utterance": "Mark Sellmyer: It's like that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. Let's do it. Let's go. ",
        "annotations": {
            "Supportive response": "The utterance expresses agreement and positive evaluation, encouraging and agreeing with the previous discussion or proposal."
        }
    },
    {
        "utterance": "Crystal Rogers: It's a great idea, but that requires a massive effort in science communication. And so if people won't take a vaccine to save their lives, I don't know that anybody would want to have a reporter uh inside of them. So I think we have these issues here. We are all for it. Like inject me, go for it, but um so there have to there has to be a a front of us being the scientists and the clinicians and also explaining how important and innocuous some of these things can be. They can be helpful. They can be, you know, therapeutic. They can also be um diagnostic but or theragnostics, right? That's the the term. But ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of genetic reporters in human beings, discussing its implications and challenges.",
            "identify gap": "The speaker highlights gaps in public acceptance and understanding of medical interventions like genetic reporters.",
            "offer feedback": "The speaker provides feedback on the need for a massive effort in science communication to make genetic reporters acceptable."
        }
    },
    {
        "utterance": "Dylan Burnette: It's like that. It's yeah. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement or alignment with previous statements, acting as a supportive response without adding new content."
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement or validation for a prior statement without adding new content."
        }
    },
    {
        "utterance": "Dylan Burnette: I I I ran into this yesterday. I was trying to I was trying to consent a patient to image their bacteria. And the question is is is your test going to help me in any way? Yeah. And the response is it can't because it's investigational as an imaging and diagnostic it will not change your management at all. The difference for the therapy folks is they're like we don't know. We're going to see it might help you. And so that's a huge like just big difference between therapeutic intervention trials and like diagnostic like, you know, approaches. Yeah. But but what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. ",
        "annotations": {
            "identify gap": "The speaker highlights a gap in understanding and communication between scientists and the general public regarding medical interventions.",
            "critical response": "The speaker expresses criticism towards the current state of communication challenges and the undervaluation of science communicators."
        }
    },
    {
        "utterance": "Dylan Burnette: and that they shouldn't be, but maybe they should, right? ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, well, there's another approach, uh, you know, when you're talking about cell-based therapies and you need to track those cells, you don't necessarily have to have a permanent, you know, imaging reporter in your body, you could just label cells before you inject them with some kind of a label that is visible for the scanner, whether it's magnetic label, you know, I'm a nanoparticle person, so obviously, um, that's what what comes to mind, but also what's biodegradable and gets, you know, gets outside your body at some point. So that doesn't seem so scary, does it? ",
        "annotations": {
            "develop idea": "Dr. Moore is expanding on previous discussions about tracking cell-based therapies by suggesting an alternative approach.",
            "propose new idea": "Dr. Moore introduces a new suggestion for tracking cells using labels detectable by scanners.",
            "signal expertise": "Dr. Moore signals her expertise in nanoparticles."
        }
    },
    {
        "utterance": "Benjamin Bartelle: longitudinally, I've I've had very little success with that. If you're trying to look at something over months, the chances you're going to find that nanoparticle laden T cell or that nanoparticle laden, you know, stem cell and have it persist over the months you need to follow the disease progression or therapy progression. Like we've been trying that for a long time since before I started grad school and it's just without having that genetic persistence, it hasn't worked. ",
        "annotations": {
            "identify gap": "The speaker highlights the challenge of tracking cells over time without genetic persistence, identifying a gap in current methods.",
            "develop idea": "The speaker elaborates on his experience with cell tracking and the limitations faced.",
            "offer feedback": "The speaker provides feedback based on his research experience, discussing the effectiveness of different approaches."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, I'm just saying like, you know, that's that's one problem with we can talk we can actually talk about that because our experience is that you could follow them for quite some time providing that cells do not divide because if they divide, then they dilute the material obviously. And and there has to be complementary methods to basically see the effect of your therapy. So you cannot kill, you know, many bunnies with one I I hate even saying that. That doesn't sound good. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the challenges of tracking cell-based therapies and suggesting practical considerations.",
            "offer feedback": "The speaker is providing practical feedback based on her experience about the need for complementary methods to assess therapy effects."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I've never heard this analogy, so. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: No. So, um, okay, so we got a, we got a warning, uh, T minus 15 minutes till the end of our. ",
        "annotations": {
            "process management": "Dr. Anna Moore is explicitly stating the time remaining for the meeting, which is a direct action of managing the meeting flow and time."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So basically what I was trying to say, I think you need more than one modality and more than one imaging, uh, you know, to even monitor one process. It seems like, you know, it has to be several different approaches just to make sure that your cells are injected, that they get where they have to go, uh, how much get lost on the way, whether they're doing what they're supposed to do, uh, and whether there's any improvement. So like right there it's like 1.5, like four, four different things that you need to monitor and you need four different ways to do that. I don't believe that there is like this universal contrast agent that can, you know, you can inject it and it's going to monitor everything. It doesn't exist. So anyway, so, um, like I said, we have, uh, 14 minutes now. ",
        "annotations": {
            "Develop idea": "Dr. Anna Moore is expanding on the idea that monitoring complex processes requires multiple approaches.",
            "Identify gap": "She implies a gap in current technology, specifically the lack of a universal contrast agent.",
            "Process management": "Dr. Anna Moore mentions the time constraint, which relates to managing the meeting process."
        }
    },
    {
        "utterance": "Sixian You: I just put down whatever I'm hearing. So I think for the next 10 minutes, can we just uh, uh, each say or just uh, input like what is the most exciting idea you heard in this meeting or you you are summarizing and we put three major ideas in in the chat instead of uh, everything. ",
        "annotations": {
            "process management": "The speaker is suggesting a way to manage the discussion for the remaining 10 minutes of the meeting, proposing that each participant shares their most exciting idea or summarizes the discussion.",
            "encourage participation": "The speaker is inviting all participants to contribute their thoughts and ideas, encouraging everyone to participate in the discussion."
        }
    },
    {
        "utterance": "Sixian You: So, so summarizing, I think um, Anna said it pretty well, so it has to be a combination of multimodal approaches uh, for these four different processes. I hear the delivery process and then the efficacy process. The other two I didn't catch it. So. ",
        "annotations": {
            "develop idea": "The speaker is building upon or elaborating on an existing idea previously discussed by Dr. Anna Moore.",
            "ask question": "The speaker seeks clarification on the processes not understood.",
            "summarize conversation": "The speaker is summarizing what has been previously discussed."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, the other thing is delivery process and then, uh, you want to be able to monitor what you delivered, if it's still there, if it's still intact, if it's still functioning. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of monitoring therapeutic delivery.",
            "identify gap": "The speaker is highlighting the need to monitor the delivery and functionality of therapeutic agents, indicating a gap in current capabilities.",
            "clarify goal": "The speaker is discussing the objectives of therapeutic development, specifically the importance of monitoring delivery and efficacy."
        }
    },
    {
        "utterance": "Dr. Anna Moore: You know, like say the cells, right? The cell therapy, uh, are they still functioning? Are they still like for example with islet transplantation, you put islets in the human body and 60% of them dead two weeks after transplantation. ",
        "annotations": {
            "develop idea": "Dr. Anna Moore is expanding on the idea of monitoring cell therapy by providing an example.",
            "ask question": "Dr. Anna Moore is explicitly asking questions about the functionality of cells in cell therapy.",
            "identify gap": "Dr. Anna Moore is highlighting a challenge in cell therapy, which is understanding what happens to the cells after transplantation."
        }
    },
    {
        "utterance": "Dr. Anna Moore: And you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely. And each, uh, islet batch comes from a donor who's obviously deceased. ",
        "annotations": {
            "identify gap": "Dr. Anna Moore explicitly recognizes the lack of knowledge about the location, function, and viability of transplanted islet cells."
        }
    },
    {
        "utterance": "Dr. Anna Moore: So it's just an example. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: Mhm. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: One idea that I think is super exciting is this idea of long-term genetic reporters. It is high risk, it is very controversial, but um, but for auto imaging they provide really good contrast and they they're they're almost forever if they don't get injected, ejected out of the body. ",
        "annotations": {
            "supportive response": "The speaker expresses enthusiasm and support for the idea of long-term genetic reporters."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Genetic reporter, I'm all for it. I have one. Anyone wants it. ",
        "annotations": {
            "supportive response": "Benjamin Bartelle is expressing agreement and support for genetic reporters.",
            "encourage participation": "Benjamin Bartelle is offering his genetic reporter to others, encouraging participation."
        }
    },
    {
        "utterance": "Benjamin Bartelle: We bring up theranostic a lot. We've said that a number of times. Um, and it's the great thing to say, um, but what exactly is a theranostic when we go through it and it neither needs to be um, some nanotechnology, some macromolecular complex that is detectable and sensitive to a specific readout or it needs to be uh an engineered cell that uh is detectable and then can change its its signal or shape. You need to have that level of complexity to have a theranostic. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of theranostics, providing his view on what it entails.",
            "ask question": "The utterance contains a question about the nature of theranostics, seeking clarification or understanding.",
            "offer feedback": "The speaker provides a perspective on theranostics, which can be seen as offering feedback on how to think about the concept."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh, it has to be for the right mechanism. ",
        "annotations": {
            "develop idea": "Benjamin Bartelle is expanding on the concept of theranostics by highlighting the necessity of an appropriate mechanism.",
            "offer feedback": "By stating that it has to be for the right mechanism, Benjamin Bartelle is providing a condition or criterion for effective theranostics."
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think that was the thing. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. ",
        "annotations": {
            "None": "The utterance 'Okay.' is a brief acknowledgment that does not explicitly fit into any of the provided codes as it does not add significant content to the discussion."
        }
    },
    {
        "utterance": "Dylan Burnette: But we haven't really talked too much about toxicity and the ability to actually detect uh tissue that is dying either through necrosis or apoptosis or some either programmed or not programmed cell death. It's something that is would be quite useful I think if you're putting drugs into people and then you want to drugs where they go where they go, but if they're causing damage along the way or when they get concentrated at the side of of where they're supposed to be at, it's hard to tell. Um, and I know in in in neurobiology if you actually saw the neurons dying that wouldn't be bad. ",
        "annotations": {
            "identify gap": "The speaker highlights a gap in the ability to detect dying tissue through necrosis or apoptosis.",
            "critical response": "The speaker critiques the current state of detecting toxicity and cell death.",
            "offer feedback": "The speaker offers that detecting cell death would be useful for drug development and administration."
        }
    },
    {
        "utterance": "Benjamin Bartelle: So you're saying cell death as a target for our imaging and theranostic then. Like understanding that. Yeah, so if you had a read out to to to actually monitor uh the the target tissues uh actual death or not because sometimes in the case of cancer you want to kill these things, but sometimes you don't want to kill it. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of using imaging and theranostics for monitoring cell death.",
            "identify gap": "The speaker highlights a gap in current capabilities, specifically in monitoring cell death in target tissues.",
            "supportive response": "The speaker is expressing agreement or validation for the concept of monitoring cell death."
        }
    },
    {
        "utterance": "Dylan Burnette: So so it could be both targeted and just a general read out of toxicity because sometimes you don't want your cells to die. Um, as a matter of fact, I don't want more of my cells to die in general. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about using imaging for monitoring cell death, considering both targeted and general toxicity readouts.",
            "supportive response": "The speaker is offering a consideration related to the previous discussion, adding a layer of complexity to the idea of monitoring cell death.",
            "offer feedback": "The speaker is providing feedback on the concept of using imaging for cell death, highlighting its potential for both targeted and general toxicity monitoring."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, a long time ago there was an an an ex in five probes developed, I would say 20 years ago to monitor tumor response to therapy. ",
        "annotations": {
            "signal expertise": "Dr. Anna Moore explicitly states her knowledge about past developments in medical probes, showing her expertise in the field."
        }
    },
    {
        "utterance": "Benjamin Bartelle: just like, oh, everything's ferroptosis, right? ",
        "annotations": {
            "express humor": "The speaker makes a comment that could be interpreted as slightly humorous or ironic, given the casual tone and the use of 'just like, oh.'"
        }
    },
    {
        "utterance": "Dylan Burnette: Um, but uh, but so it's it's probably impossible to have one particular marker to pull off, you know, actually knowing what kind of of cell death, but it would be nice to know if cells are alive or not inside of of a biotic. ",
        "annotations": {
            "identify gap": "The speaker highlights the difficulty in having a single marker for determining the type of cell death, indicating a gap in current capabilities.",
            "propose new idea": "The speaker suggests that being able to determine if cells are alive or not within a biotic context would be beneficial, proposing a direction for future research."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. So, um, so let's see. So, um, Sision, do you do you feel comfortable talking about those things? ",
        "annotations": {
            "ask question": "The speaker is directly asking Sision if they feel comfortable discussing certain topics.",
            "encourage participation": "The speaker is directly inviting Sision to contribute their thoughts or opinions."
        }
    },
    {
        "utterance": "Sixian You: Actually, uh, yeah, I I think I can only catch understand like 50% of these conversations. I think my biology is probably high school level, so. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes his own lack of knowledge or familiarity in a particular domain, which is biology, stating his understanding level is only at a high school level."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's pretty good though. 50%'s pretty good. ",
        "annotations": {
            "supportive response": "Benjamin Bartelle is expressing agreement and validation of Sixian You's statement about only understanding 50% of the conversation."
        }
    },
    {
        "utterance": "Sixian You: So if anybody wants to take over, I'm totally comfortable because I think the best thing is that we present the best ideas in the room. Um, yeah. ",
        "annotations": {
            "code name": "supportive response",
            "explanation": "The speaker expresses a positive sentiment towards the discussion and the presentation of ideas."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Nah, you got this. Come on. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and encouragement.",
            "encourage participation": "The speaker is inviting or encouraging someone to continue or participate."
        }
    },
    {
        "utterance": "Sixian You: Okay. So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Do we we have our our barriers, our targets, our agents, our approaches. This is all getting really well organized, so I. ",
        "annotations": {
            "ask question": "The speaker is requesting information or confirmation about whether they have covered all necessary aspects (barriers, targets, agents, approaches).",
            "process management": "The speaker is commenting on the progress and organization of the discussion."
        }
    },
    {
        "utterance": "Sixian You: Oh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think it's really shaping up. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive sentiment about the progress or organization of the discussion."
        }
    },
    {
        "utterance": "Sixian You: Okay. So, uh, I guess to start, we can kind of present to the room like what are the barriers? Uh, and the barriers of course, disparity between the models and uh, the lack of understanding, uh, and the lack of tools to um, to validate toxicity and efficacy uh, in the short timeline. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes the lack of understanding, the disparity between models, and the lack of tools to validate toxicity and efficacy as significant gaps."
        }
    },
    {
        "utterance": "Sixian You: And then to address that, we could first we could um, focus more efforts on different targets, uh, list at this and then contrast agency is another effort and then uh, in the end it will be a combination multi model approaches of all this. ",
        "annotations": {
            "propose new idea": "The speaker suggests focusing efforts on different targets and considering contrast agents as part of the approach.",
            "develop idea": "The speaker builds upon existing ideas by suggesting specific actions and a multi-model approach to address the challenges discussed."
        }
    },
    {
        "utterance": "Sixian You: Where does imaging come in? The multimodal approaches in the contrast agents? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the role of imaging, particularly multimodal approaches and contrast agents, in the context of the discussion."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. I mean that's what we mean by multimodal, multimodal imaging. ",
        "annotations": {
            "develop idea": "Benjamin Bartelle is expanding on the concept of multimodal imaging, providing a clearer understanding of what it entails.",
            "supportive response": "By clarifying the term 'multimodal imaging,' Benjamin Bartelle is supporting the discussion and ensuring everyone understands the concept."
        }
    },
    {
        "utterance": "Crystal Rogers: Well, and also in the technological development, right, to be able to actually see the efficacy of these things live in an organism. Someday. ",
        "annotations": {
            "develop idea": "The speaker expands on the idea that technological development is necessary for understanding and monitoring the efficacy of treatments in organisms.",
            "identify gap": "The utterance implies a gap in current technology, specifically in being able to see the efficacy of treatments in live organisms.",
            "supportive response": "The utterance is supportive in nature, aligning with previous discussions on the need for technological advancements."
        }
    },
    {
        "utterance": "Benjamin Bartelle: Is is is multimodal approaches a subset of technological development then? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the relationship between two concepts: multimodal approaches and technological development."
        }
    },
    {
        "utterance": "Crystal Rogers: It is. Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it's a very brief agreement."
        }
    },
    {
        "utterance": "Sixian You: Yeah. Uh-huh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: I guess all this stuff then. These things are all like uh development of 3D culture, visualization of delivery. That's all tech development that we're all tracking. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the discussion by framing it in terms of technological development.",
            "process management": "The speaker shows awareness of the group's focus on technological development, indicating an understanding of the meeting's goals."
        }
    },
    {
        "utterance": "Sixian You: So, I can delete this and uh, put multimodal approaches here. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Crystal Rogers: I think the 3D cell culture stuff is also part of technological development, bioprinting, etc. ",
        "annotations": {
            "develop idea": "The speaker is expanding, building upon, or elaborating existing ideas through reasoning and examples."
        }
    },
    {
        "utterance": "Sixian You: Uh, that is also, okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sixian You: I think we talked about this before. Yeah, particle, nanoparticle is already in the contrast agents. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Benjamin Bartelle: You can make the the font smaller too if it doesn't fit. That's uh that's the easy one. ",
        "annotations": {
            "process management": "The speaker is making a practical comment about adjusting the font size for presentation purposes, which relates to managing the flow or preparation of the presentation.",
            "express humor": "The speaker's comment is lighthearted and humorous, as indicated by the casual tone and the phrase 'that's the easy one.'"
        }
    },
    {
        "utterance": "Morteza Mahmoudi: I also want to add the concept of like live contrast agents, like what happens with magnetotactic bacteria because like the dilution of the like the contrast agent is a big problem in the like the cell proliferation. ",
        "annotations": {
            "propose new idea": "The speaker introduces the concept of 'live contrast agents' and suggests using magnetotactic bacteria as an example to address the issue of contrast agent dilution in cell proliferation imaging."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. ",
        "annotations": {
            "develop idea": "The speaker is expanding and clarifying existing ideas through reasoning and examples."
        }
    },
    {
        "utterance": "Morteza Mahmoudi: So the live contrast like there are papers coming out showing basically that magnetotactic bacteria can be used for like even increasing the like uh imaging uh sensitivity and capacity at the side of like for cell therapy applications, they they at least they showed promising results. So maybe adding. ",
        "annotations": {
            "propose new idea": "Morteza Mahmoudi introduces the idea of using magnetotactic bacteria to increase imaging sensitivity and capacity for cell therapy applications.",
            "develop idea": "He references papers showing promising results for the use of magnetotactic bacteria in cell therapy applications."
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. It's a a live reporter. I mean, I I agree. I agree with you completely. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and validation of another group member's contribution without adding new content."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, we have uh probably one or a little bit over one minute left. So I just wanted to say that uh I I think it was fun. I think you know, I think we discussed a lot of different questions because the topic is so broad. And um if you guys you know, if you guys want to talk more about it, you know, my email is there. Uh you can email me or you can email each other. Please, um and uh hopefully we'll get this going and uh I'm looking forward to forming proposals from you guys. Just think what what you want to do. Um, you have complimentary expertise. Um, so we have a clinical person here. That's unique. So grab his expertise before it's too late. ",
        "annotations": {
            "Signal expertise": "Dr. Anna Moore highlights the unique expertise of a clinical person present.",
            "Supportive response": "Dr. Anna Moore expresses positive sentiments about the discussion.",
            "Summarize conversation": "Dr. Anna Moore summarizes that they discussed a lot of different questions.",
            "Encourage participation": "Dr. Anna Moore invites others to discuss further and form proposals.",
            "Process management": "Dr. Anna Moore mentions the time constraint."
        }
    },
    {
        "utterance": "Lisa Poulikakos: Thanks everyone. I feel like I learned a lot as a physics engineering person and I really appreciated the discussion. ",
        "annotations": {
            "supportive response": "The speaker is expressing appreciation and positive evaluation of the discussion."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Dr. Anna Moore: Me too. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a previous statement, showing support without adding new information."
        }
    },
    {
        "utterance": "Sixian You: Yeah, I learned all the all the dark size and potentially price size of therapy. What I learned again is biology is so hard and medicine is so hard. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes the difficulties and complexities in biology and medicine, indicating a gap in current understanding or capabilities."
        }
    },
    {
        "utterance": "Lisa Poulikakos: I really really liked what Crystal said about the communication being key as we do push forward with anything shiny and new. ",
        "annotations": {
            "acknowledge contribution": "Lisa acknowledges Crystal's contribution to the discussion.",
            "supportive response": "Lisa expresses agreement and validation for Crystal's point about communication being key."
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I totally agree. ",
        "annotations": {
            "None": "The speaker is simply agreeing with a previous statement without adding any new content."
        }
    },
    {
        "utterance": "Dylan Burnette: And I liked what Molly said about the difficulty with integrating over time scales and and having tractable metrics for many of the different diseases. ",
        "annotations": {
            "supportive response": "Dylan Burnette is expressing agreement and validation with Molly Bright's comment about the difficulty of integrating over time scales and having tractable metrics for many diseases."
        }
    }
]